Loading clinical trials...
Loading clinical trials...
The goal of this clinical trial is to evaluate if the investigational drug, RL-007, can improve the cognitive performance of subjects with schizophrenia. The main questions the study aims to answer ar...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Recognify Life Sciences
NCT05877196 · Mild Cognitive Impairment, Alzheimer Disease, and more
NCT06894212 · Schizophrenia
NCT06223672 · Cognitive Decline, Cognitive Impairment
NCT07101380 · Mild Cognitive Impairment (MCI)
NCT06095297 · Long COVID, Brain Fog, and more
Recognify Research Site
Culver City, California
Collaborative Neuroscience Research
Garden Grove, California
Recognify Research Site
Lafayette, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions